​

Insmed (INSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INSM Stock Forecast

Insmed stock forecast is as follows: an average price target of $88.50 (represents a 13.46% upside from INSM’s last price of $78.00) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

INSM Price Target

The average price target for Insmed (INSM) is $88.50 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $92.00 to $85.00. This represents a potential 13.46% upside from INSM's last price of $78.00.

INSM Analyst Ratings

Buy

According to 14 Wall Street analysts, Insmed's rating consensus is 'Buy'. The analyst rating breakdown for INSM stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 0 'Hold' (0.00%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).

Insmed Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 15, 2024Graig SuvannavejhMizuho Securities$92.00$73.4325.29%17.95%
Aug 09, 2024Tiago FauthWells Fargo$85.00$71.8118.37%8.97%
Jul 09, 2024Vamil DivanGuggenheim$95.00$70.0535.62%21.79%
Jul 01, 2024Nicole GerminoTruist Financial$88.00$67.0031.34%12.82%
Jun 25, 2024Leon WangBarclays$90.00$69.7129.11%15.38%
Jun 21, 2024Liisa BaykoEvercore ISI$75.00$66.1913.31%-3.85%
Jun 07, 2024Graig SuvannavejhMizuho Securities$82.00$57.1743.43%5.13%
Jun 05, 2024Stephen WilleyStifel Nicolaus$74.00$57.0029.82%-5.13%
May 29, 2024Tiago FauthWells Fargo$77.00$53.5543.79%-1.28%
May 29, 2024Andrew FeinH.C. Wainwright$70.00$48.0645.65%-10.26%
May 29, 2024Trung HuynhUBS$58.00$48.0620.68%-25.64%
May 29, 2024Nicole GerminoTruist Financial$68.00$48.0641.49%-12.82%
May 29, 2024Andy ChenWolfe Research$54.00$48.0612.36%-30.77%
May 28, 2024Jeffrey HungMorgan Stanley$60.00$48.0624.84%-23.08%
May 28, 2024Andrea TanGoldman Sachs$74.00$46.3959.52%-5.13%
May 28, 2024Liisa BaykoEvercore ISI$42.00$46.21-9.11%-46.15%
May 13, 2024Graig SuvannavejhMizuho Securities$36.00$25.3342.12%-53.85%
May 09, 2024Jeffrey HungMorgan Stanley$43.00$26.3863.00%-44.87%
Apr 23, 2024Nicole GerminoTruist Financial$48.00$24.1199.09%-38.46%
Apr 01, 2024Tiago FauthWells Fargo$55.00$27.13102.73%-29.49%
Apr 27, 2022Goldman Sachs$56.00$22.22152.03%-28.21%

The latest Insmed stock forecast, released on Aug 15, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $92.00, which represents a 25.29% increase from the stock price at the time of the forecast ($73.43), and a 17.95% increase from INSM last price ($78.00).

Insmed Price Target by Period

1M3M12M
# Anlaysts--20
Avg Price Target--$68.30
Last Closing Price$78.00$78.00$78.00
Upside/Downside-100.00%-100.00%-12.44%

In the current month, the average price target of Insmed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Insmed's last price of $78.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 09, 2024Cowen & Co.BuyBuyHold
Aug 09, 2024Wells FargoOverweightOverweightHold
Jul 12, 2024Morgan StanleyOverweightOverweightHold
Jul 09, 2024GuggenheimBuyBuyHold
Jul 05, 2024Cowen & Co.BuyBuyHold
Jul 02, 2024H.C. WainwrightBuyBuyHold
Jun 25, 2024BarclaysOverweightOverweightHold
Jun 21, 2024Evercore ISIOutperformOutperformHold
May 29, 2024H.C. WainwrightBuyBuyHold
May 29, 2024Wells FargoOverweightOverweightHold
May 29, 2024UBSBuyBuyHold
May 29, 2024Wolfe ResearchOutperformOutperformHold
May 29, 2024Bank of America SecuritiesBuyBuyHold
May 28, 2024BarclaysOverweightOverweightHold
May 28, 2024Goldman SachsBuyBuyHold
May 28, 2024Cowen & Co.BuyBuyHold
May 28, 2024Evercore ISIOutperformOutperformHold
May 09, 2024Morgan StanleyOverweightOverweightHold
Apr 01, 2024Wells FargoOverweightOverweightHold
Apr 27, 2022Goldman SachsBuyInitialise
Apr 26, 2022Zacks Investment ResearchSellDowngrade
Feb 22, 2022SVB LeerinkOutperformOutperformHold
Oct 11, 2021Cantor FitzgeraldOverweightInitialise

Insmed's last stock rating was published by Cowen & Co. on Aug 09, 2024. The company gave INSM a "Buy" rating, the same as its previous rate.

Insmed Financial Forecast

Insmed Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 16
Revenue---------$79.07M-$65.21M$59.30M$67.73M$65.22M$53.11M$56.12M$46.76M$45.37M$40.21M$41.41M$43.64M$42.49M$36.86M$45.71M$38.88M$29.97M$21.90M--
Avg Forecast$149.23M$116.33M$101.77M$89.10M$98.53M$93.36M$87.95M$77.76M$81.88M$79.14M$70.23M$64.25M$62.09M$66.85M$58.79M$53.28M$50.35M$48.22M$43.72M$41.64M$41.44M$46.07M$34.51M$34.80M$45.06M$35.89M$25.76M$19.62M$35.95M$12.98M
High Forecast$152.87M$119.16M$104.24M$91.34M$105.27M$93.57M$87.95M$77.76M$82.13M$83.24M$71.94M$65.81M$65.43M$66.85M$58.79M$53.28M$50.35M$48.22M$43.72M$41.64M$41.44M$46.07M$34.51M$34.80M$45.06M$35.89M$25.76M$19.62M$43.15M$15.58M
Low Forecast$146.02M$113.83M$99.57M$86.86M$92.76M$93.15M$87.95M$77.76M$81.74M$77.71M$68.72M$62.86M$59.88M$66.85M$58.79M$53.28M$50.35M$48.22M$43.72M$41.64M$41.44M$46.07M$34.51M$34.80M$45.06M$35.89M$25.76M$19.62M$28.76M$10.39M
# Analysts1112109113964374347444889127781613
Surprise %---------1.00%-1.02%0.96%1.01%1.11%1.00%1.11%0.97%1.04%0.97%1.00%0.95%1.23%1.06%1.01%1.08%1.16%1.12%--

Insmed's average Quarter revenue forecast for Dec 23 based on 3 analysts is $81.88M, with a low forecast of $81.74M, and a high forecast of $82.13M. INSM's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $79.07M (Sep 23).

Insmed EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 16
# Analysts1112109113964374347444889127781613
EBITDA---------$-136.80M-$-147.01M$-149.08M$-127.10M$-91.22M$-89.36M$-98.83M$-101.09M$-103.19M$-80.54M$-90.87M$-52.96M$-50.79M$-55.39M$-42.12M$-51.78M$-57.56M$-65.24M$-62.41M$-32.37M
Avg Forecast$-149.23M$-116.33M$-101.77M$-89.10M$-98.53M$-93.36M$-87.95M$-117.77M$-81.88M$-79.14M$-70.23M$-107.06M$-101.38M$-66.85M$-58.79M$-97.33M$-50.35M$-48.22M$-43.72M$-79.63M$-41.44M$-46.07M$-34.51M$-53.05M$-45.06M$-35.89M$-25.76M$-64.56M$-67.67M$-33.72M
High Forecast$-146.02M$-113.83M$-99.57M$-86.86M$-92.76M$-93.15M$-87.95M$-94.21M$-81.74M$-77.71M$-68.72M$-85.65M$-81.11M$-66.85M$-58.79M$-77.86M$-50.35M$-48.22M$-43.72M$-63.70M$-41.44M$-46.07M$-34.51M$-42.44M$-45.06M$-35.89M$-25.76M$-51.65M$-54.14M$-26.97M
Low Forecast$-152.87M$-119.16M$-104.24M$-91.34M$-105.27M$-93.57M$-87.95M$-141.32M$-82.13M$-83.24M$-71.94M$-128.47M$-121.66M$-66.85M$-58.79M$-116.79M$-50.35M$-48.22M$-43.72M$-95.55M$-41.44M$-46.07M$-34.51M$-63.66M$-45.06M$-35.89M$-25.76M$-77.47M$-81.21M$-40.46M
Surprise %---------1.73%-1.37%1.47%1.90%1.55%0.92%1.96%2.10%2.36%1.01%2.19%1.15%1.47%1.04%0.93%1.44%2.23%1.01%0.92%0.96%

undefined analysts predict INSM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Insmed's previous annual EBITDA (undefined) of $NaN.

Insmed Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 16
# Analysts1112109113964374347444889127781613
Net Income---------$-158.93M-$-159.76M$-160.12M$-131.15M$-95.64M$-94.62M$-112.98M$-112.71M$-117.32M$-91.64M$-102.21M$-63.66M$-61.85M$-66.36M$-52.99M$-60.68M$-66.51M$-74.15M$-68.52M$-33.53M
Avg Forecast$-210.20M$-237.13M$-224.53M$-223.67M$-202.33M$-208.84M$-216.19M$-124.90M$-200.32M$-198.23M$-196.96M$-113.55M$-115.90M$-135.92M$-137.24M$-103.22M$-139.19M$-132.79M$-138.24M$-90.60M$-107.37M$-91.72M$-95.92M$-63.56M$-87.32M$-103.14M$-132.60M$-73.37M$-74.82M$-34.73M
High Forecast$-204.31M$-230.48M$-218.24M$-218.25M$-183.14M$-202.99M$-210.13M$-99.92M$-184.37M$-159.29M$-191.44M$-90.84M$-92.72M$-135.92M$-137.24M$-82.58M$-139.19M$-132.79M$-138.24M$-72.48M$-107.37M$-91.72M$-95.92M$-50.85M$-87.32M$-103.14M$-132.60M$-58.70M$-59.85M$-27.78M
Low Forecast$-216.85M$-244.63M$-231.64M$-227.27M$-221.51M$-215.45M$-223.03M$-149.88M$-226.92M$-226.55M$-203.19M$-136.25M$-139.08M$-135.92M$-137.24M$-123.87M$-139.19M$-132.79M$-138.24M$-108.72M$-107.37M$-91.72M$-95.92M$-76.27M$-87.32M$-103.14M$-132.60M$-88.05M$-89.78M$-41.68M
Surprise %---------0.80%-1.41%1.38%0.96%0.70%0.92%0.81%0.85%0.85%1.01%0.95%0.69%0.64%1.04%0.61%0.59%0.50%1.01%0.92%0.97%

Insmed's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. INSM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Insmed SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 16
# Analysts1112109113964374347444889127781613
SG&A---------$90.63M-$79.91M$73.48M$80.82M$47.35M$56.75M$65.27M$60.28M$57.18M$51.55M$56.02M$46.59M$49.66M$52.59M$51.45M$54.60M$53.68M$56.06M$32.65M$12.52M
Avg Forecast$186.19M$145.14M$126.97M$111.16M$122.93M$116.48M$109.73M$74.91M$102.15M$98.74M$87.62M$80.16M$77.46M$83.41M$73.35M$66.47M$62.81M$60.17M$54.55M$51.95M$51.70M$57.48M$43.06M$43.42M$56.22M$44.78M$32.14M$24.48M$35.65M$12.97M
High Forecast$190.72M$148.67M$130.06M$113.95M$131.33M$116.74M$109.73M$89.89M$102.47M$103.85M$89.76M$82.11M$81.64M$83.41M$73.35M$66.47M$62.81M$60.17M$54.55M$51.95M$51.70M$57.48M$43.06M$43.42M$56.22M$44.78M$32.14M$24.48M$42.78M$15.56M
Low Forecast$182.17M$142.01M$124.23M$108.38M$115.73M$116.22M$109.73M$59.93M$101.98M$96.95M$85.73M$78.43M$74.70M$83.41M$73.35M$66.47M$62.81M$60.17M$54.55M$51.95M$51.70M$57.48M$43.06M$43.42M$56.22M$44.78M$32.14M$24.48M$28.52M$10.37M
Surprise %---------0.92%-1.00%0.95%0.97%0.65%0.85%1.04%1.00%1.05%0.99%1.08%0.81%1.15%1.21%0.92%1.22%1.67%2.29%0.92%0.97%

Insmed's average Quarter SG&A projection for Dec 23 is $102.15M, based on 3 Wall Street analysts, with a range of $101.98M to $102.47M. The forecast indicates a 12.72% rise compared to INSM last annual SG&A of $90.63M (Sep 23).

Insmed EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 16
# Analysts1112109113964374347444889127781613
EPS---------$-1.11-$-1.17$-1.21$-1.09$-0.80$-0.80$-0.95$-0.96$-1.07$-0.89$-1.00$-0.63$-0.64$-0.74$-0.59$-0.68$-0.81$-0.96$-0.89$-0.54
Avg Forecast$-1.21$-1.36$-1.29$-1.29$-1.16$-1.20$-1.24$-1.24$-1.15$-1.14$-1.13$-1.13$-1.05$-0.88$-0.89$-0.88$-0.90$-0.86$-0.89$-0.94$-0.69$-0.59$-0.62$-0.72$-0.56$-0.67$-0.86$-0.95$-1.07$-0.58
High Forecast$-1.18$-1.33$-1.26$-1.26$-1.05$-1.17$-1.21$-1.20$-1.06$-0.92$-1.10$-1.10$-1.00$-0.88$-0.89$-0.88$-0.90$-0.86$-0.89$-0.94$-0.69$-0.59$-0.62$-0.72$-0.56$-0.67$-0.86$-0.95$-0.86$-0.46
Low Forecast$-1.25$-1.41$-1.33$-1.31$-1.28$-1.24$-1.28$-1.28$-1.31$-1.30$-1.17$-1.16$-1.12$-0.88$-0.89$-0.88$-0.90$-0.86$-0.89$-0.94$-0.69$-0.59$-0.62$-0.72$-0.56$-0.67$-0.86$-0.95$-1.28$-0.70
Surprise %---------0.97%-1.04%1.16%1.24%0.90%0.91%1.06%1.12%1.20%0.94%1.44%1.06%1.03%1.02%1.05%1.02%0.95%1.01%0.83%0.93%

According to undefined Wall Street analysts, Insmed's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to INSM previous annual EPS of $NaN (undefined).

Insmed Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KROSKeros Therapeutics$11.37$101.00788.30%Buy
FENCFennec Pharmaceuticals$6.47$15.75143.43%Buy
APLSApellis Pharmaceuticals$29.47$70.80140.24%Buy
RAREUltragenyx Pharmaceutical$42.47$90.00111.91%Buy
SWTXSpringWorks Therapeutics$36.52$77.00110.84%Buy
RNAAvidity Biosciences$31.92$59.0084.84%Buy
DAWNDay One Biopharmaceuticals$13.01$24.0084.47%Buy
ASNDAscendis Pharma$127.55$211.1465.54%Buy
RVMDRevolution Medicines$40.92$67.6765.37%Buy
JANXJanux Therapeutics$42.51$70.2565.26%Buy
EWTXEdgewise Therapeutics$28.42$46.2562.74%Buy
AGIOAgios Pharmaceuticals$33.73$53.5058.61%Buy
BGNEBeiGene$184.71$267.3344.73%Buy
HRMYHarmony Biosciences$38.82$45.3316.77%Buy
INSMInsmed$78.00$88.5013.46%Buy
BPMCBlueprint Medicines$114.32$127.0011.09%Buy
HALOHalozyme Therapeutics$55.83$52.00-6.86%Buy
AKROAkero Therapeutics$54.00$50.00-7.41%Buy

INSM Forecast FAQ

Is Insmed a good buy?

Yes, according to 14 Wall Street analysts, Insmed (INSM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of INSM's total ratings.

What is INSM's price target?

Insmed (INSM) average price target is $88.5 with a range of $85 to $92, implying a 13.46% from its last price of $78. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Insmed stock go up soon?

According to Wall Street analysts' prediction for INSM stock, the company can go up by 13.46% (from the last price of $78 to the average price target of $88.5), up by 17.95% based on the highest stock price target, and up by 8.97% based on the lowest stock price target.

Can Insmed stock reach $120?

INSM's average twelve months analyst stock price target of $88.5 does not support the claim that Insmed can reach $120 in the near future.

What are Insmed's analysts' financial forecasts?

Insmed's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $357.6M (high $364.55M, low $351.63M), average EBITDA is $-398M (high $-368M, low $-428M), average net income is $-752M (high $-696M, low $-810M), average SG&A $424.05M (high $447.7M, low $401.61M), and average EPS is $-4.849 (high $-4.635, low $-5.076). INSM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $456.43M (high $467.61M, low $446.28M), average EBITDA is $-456M (high $-446M, low $-468M), average net income is $-896M (high $-871M, low $-920M), average SG&A $569.46M (high $583.4M, low $556.79M), and average EPS is $-5.155 (high $-5.015, low $-5.298).

Did the INSM's actual financial results beat the analysts' financial forecasts?

Based on Insmed's last annual report (Dec 2022), the company's revenue was $245.36M, beating the average analysts forecast of $241.01M by 1.80%. Apple's EBITDA was $-458M, beating the average prediction of $-324M by 41.27%. The company's net income was $-482M, missing the average estimation of $-492M by -2.18%. Apple's SG&A was $265.78M, missing the average forecast of $300.7M by -11.61%. Lastly, the company's EPS was $-3.91, beating the average prediction of $-3.694 by 5.84%. In terms of the last quarterly report (Sep 2023), Insmed's revenue was $79.07M, missing the average analysts' forecast of $79.14M by -0.08%. The company's EBITDA was $-137M, beating the average prediction of $-79.138M by 72.87%. Insmed's net income was $-159M, missing the average estimation of $-198M by -19.82%. The company's SG&A was $90.63M, missing the average forecast of $98.74M by -8.21%. Lastly, the company's EPS was $-1.11, missing the average prediction of $-1.141 by -2.72%